A 20-year-old man from Van Dyne shot himself in the hand while visiting with family. Police say the man disassembled the handgun and was putting it back together. He didn’t realize the gun was ...

Dyne Therapeutics, Inc. engages in developing innovative life-transforming therapies for genetically driven muscle diseases. It develops a broad portfolio of therapeutics for muscle diseases ...

Dyne Therapeutics (NASDAQ:DYN – Free Report) had its target price reduced by HC Wainwright from $55.00 to $46.00 in a research report report published on Friday morning,Benzinga reports.

Shares of NASDAQ:DYN opened at $13.61 on Friday. Dyne Therapeutics has a 52-week low of $12.87 and a 52-week high of $47.45. The business has a fifty day moving average of $16.98 and a two-hundred ...

When Might Dyne Therapeutics Run Out Of Money? A company's cash runway is calculated by dividing its cash hoard by its cash burn. When Dyne Therapeutics last reported its December 2024 balance ...

Feb. 14, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage neuromuscular disease company focused on advancing life-transforming therapeutics for people living with ...

Full enrollment of Registrational Expansion Cohort of ACHIEVE Trial of DYNE-101 in DM1 Planned for Mid-2025 to Support Submission for U.S. Accelerated Approval - - Full Enrollment of ...

Full enrollment of Registrational Expansion Cohort of ACHIEVE Trial of DYNE-101 in DM1 Planned for Mid-2025 to Support Submission for U.S. Accelerated Approval - - Full Enrollment of Registrational ...